BR112013000599A2 - deuterado n-etil-n-fenil-1,2-di-hidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolino-3-carboxamida, os seus sais e suas utilizações - Google Patents
deuterado n-etil-n-fenil-1,2-di-hidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolino-3-carboxamida, os seus sais e suas utilizaçõesInfo
- Publication number
- BR112013000599A2 BR112013000599A2 BR112013000599A BR112013000599A BR112013000599A2 BR 112013000599 A2 BR112013000599 A2 BR 112013000599A2 BR 112013000599 A BR112013000599 A BR 112013000599A BR 112013000599 A BR112013000599 A BR 112013000599A BR 112013000599 A2 BR112013000599 A2 BR 112013000599A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxoquinoline
- carboxamide
- dihydro
- chloro
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
deuterado n-etil-n-fenil-1,2-di-hidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolino-3-carboxamida, os seus sais e suas utilizações. a presente invenção proporciona deuterado n-etil-n-fenil-1, 2-di-hidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolino-3-carboxamida, seus sais e seus usos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39929710P | 2010-07-09 | 2010-07-09 | |
PCT/US2011/043383 WO2012006538A1 (en) | 2010-07-09 | 2011-07-08 | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013000599A2 true BR112013000599A2 (pt) | 2016-07-05 |
Family
ID=45439026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013000599A BR112013000599A2 (pt) | 2010-07-09 | 2011-07-08 | deuterado n-etil-n-fenil-1,2-di-hidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolino-3-carboxamida, os seus sais e suas utilizações |
Country Status (19)
Country | Link |
---|---|
US (3) | US8580819B2 (pt) |
EP (2) | EP3213636A1 (pt) |
JP (2) | JP2013535437A (pt) |
KR (1) | KR20130092558A (pt) |
CN (2) | CN104610144A (pt) |
AR (1) | AR082150A1 (pt) |
AU (1) | AU2011274496B2 (pt) |
BR (1) | BR112013000599A2 (pt) |
CA (1) | CA2804986A1 (pt) |
CL (1) | CL2013000063A1 (pt) |
EA (1) | EA025377B1 (pt) |
IL (1) | IL251600A0 (pt) |
MX (1) | MX2013000333A (pt) |
NZ (1) | NZ606587A (pt) |
PE (1) | PE20130396A1 (pt) |
SG (2) | SG10201505236YA (pt) |
UY (1) | UY33504A (pt) |
WO (1) | WO2012006538A1 (pt) |
ZA (1) | ZA201300956B (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0617477A2 (pt) * | 2005-10-19 | 2011-07-26 | Teva Pharma | mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica |
PT2035001E (pt) | 2006-06-12 | 2012-02-06 | Teva Pharma | Preparações de laquinimod estáveis |
PT2234485E (pt) | 2007-12-20 | 2014-02-17 | Teva Pharma | Preparações de laquinimod estáveis |
CN107308162A (zh) * | 2009-06-19 | 2017-11-03 | 泰华制药工业有限公司 | 利用拉喹莫德治疗多发性硬化 |
ES2564931T3 (es) * | 2009-07-30 | 2016-03-30 | Teva Pharmaceutical Industries Ltd. | Tratamiento de enfermedad de Crohn con laquinimod |
EP3064206B1 (en) | 2009-08-10 | 2019-03-20 | Active Biotech AB | Treatment of huntington's disease using laquinimod |
KR20160129093A (ko) * | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
JP5819328B2 (ja) * | 2010-03-03 | 2015-11-24 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 |
SG183515A1 (en) * | 2010-03-03 | 2012-10-30 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
SG10201505236YA (en) * | 2010-07-09 | 2015-08-28 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
MX2014004420A (es) | 2011-10-12 | 2014-07-09 | Teva Pharma | Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod. |
AU2013214909A1 (en) | 2012-02-03 | 2014-09-18 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy |
SG11201404419WA (en) | 2012-02-16 | 2014-10-30 | Teva Pharma | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
WO2014086284A1 (zh) * | 2012-12-04 | 2014-06-12 | 上海医药集团股份有限公司 | 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途 |
EP2968203A1 (en) | 2013-03-14 | 2016-01-20 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
CN103145562B (zh) * | 2013-03-18 | 2015-06-17 | 黄河三角洲京博化工研究院有限公司 | 一种n-乙基苯胺的制备方法 |
EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
EP3347006B1 (en) | 2015-03-20 | 2022-07-27 | GABA Therapeutics Inc. | Deuterated analogs of etifoxine, their derivatives and uses therof |
JP7226565B2 (ja) * | 2019-08-28 | 2023-02-21 | 日産自動車株式会社 | 物体認識方法、及び、物体認識装置 |
US11534434B2 (en) | 2019-11-15 | 2022-12-27 | Karuna Therapeutics, Inc. | Xanomeline derivatives and methods for treating neurological disorders |
JP2023509336A (ja) * | 2019-12-19 | 2023-03-08 | アクティブ バイオテック エービー | 過剰血管新生に関連する眼疾患を治療する化合物 |
GB202006390D0 (en) * | 2020-04-30 | 2020-06-17 | Aqilion Ab | Novel treatments |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
EP1187601B1 (en) | 1999-06-07 | 2005-07-27 | ALTANA Pharma AG | Novel preparation and administration form comprising an acid-labile proton pump inhibitor |
US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
BRPI0617477A2 (pt) | 2005-10-19 | 2011-07-26 | Teva Pharma | mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica |
PT2035001E (pt) | 2006-06-12 | 2012-02-06 | Teva Pharma | Preparações de laquinimod estáveis |
US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
PT2234485E (pt) | 2007-12-20 | 2014-02-17 | Teva Pharma | Preparações de laquinimod estáveis |
CN104311486A (zh) * | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-羰基-1,2-二氢喹啉免疫功能调节剂 |
CN107308162A (zh) | 2009-06-19 | 2017-11-03 | 泰华制药工业有限公司 | 利用拉喹莫德治疗多发性硬化 |
JP2011001308A (ja) * | 2009-06-19 | 2011-01-06 | Research Foundation Itsuu Laboratory | 重水素化カルボスチリル化合物 |
ES2564931T3 (es) | 2009-07-30 | 2016-03-30 | Teva Pharmaceutical Industries Ltd. | Tratamiento de enfermedad de Crohn con laquinimod |
EP3064206B1 (en) | 2009-08-10 | 2019-03-20 | Active Biotech AB | Treatment of huntington's disease using laquinimod |
JP5819328B2 (ja) | 2010-03-03 | 2015-11-24 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 |
KR20160129093A (ko) | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
SG183515A1 (en) | 2010-03-03 | 2012-10-30 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
SG10201505236YA (en) * | 2010-07-09 | 2015-08-28 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
WO2012006544A1 (en) | 2010-07-09 | 2012-01-12 | Teva Pharmaceutical Industries Ltd. | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
UA111959C2 (uk) | 2010-12-07 | 2016-07-11 | Тева Фармасьютікл Індастріз Лтд. | Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом |
-
2011
- 2011-07-08 SG SG10201505236YA patent/SG10201505236YA/en unknown
- 2011-07-08 JP JP2013519724A patent/JP2013535437A/ja not_active Withdrawn
- 2011-07-08 PE PE2013000039A patent/PE20130396A1/es not_active Application Discontinuation
- 2011-07-08 AR ARP110102478A patent/AR082150A1/es unknown
- 2011-07-08 US US13/178,842 patent/US8580819B2/en not_active Expired - Fee Related
- 2011-07-08 MX MX2013000333A patent/MX2013000333A/es unknown
- 2011-07-08 CN CN201410831557.XA patent/CN104610144A/zh active Pending
- 2011-07-08 AU AU2011274496A patent/AU2011274496B2/en not_active Ceased
- 2011-07-08 EP EP16196628.8A patent/EP3213636A1/en not_active Withdrawn
- 2011-07-08 EP EP20110804411 patent/EP2597954A4/en not_active Withdrawn
- 2011-07-08 CA CA2804986A patent/CA2804986A1/en not_active Abandoned
- 2011-07-08 KR KR1020137003480A patent/KR20130092558A/ko not_active Application Discontinuation
- 2011-07-08 EA EA201390081A patent/EA025377B1/ru not_active IP Right Cessation
- 2011-07-08 NZ NZ60658711A patent/NZ606587A/en not_active IP Right Cessation
- 2011-07-08 WO PCT/US2011/043383 patent/WO2012006538A1/en active Application Filing
- 2011-07-08 BR BR112013000599A patent/BR112013000599A2/pt not_active IP Right Cessation
- 2011-07-08 SG SG2013000948A patent/SG186948A1/en unknown
- 2011-07-08 CN CN2011800340883A patent/CN102984939A/zh active Pending
- 2011-07-11 UY UY0001033504A patent/UY33504A/es not_active Application Discontinuation
-
2013
- 2013-01-08 CL CL2013000063A patent/CL2013000063A1/es unknown
- 2013-02-05 ZA ZA2013/00956A patent/ZA201300956B/en unknown
- 2013-10-24 US US14/062,685 patent/US20140051723A1/en not_active Abandoned
-
2014
- 2014-03-14 US US14/213,279 patent/US9102620B2/en not_active Expired - Fee Related
-
2016
- 2016-07-28 JP JP2016148514A patent/JP2017014238A/ja active Pending
-
2017
- 2017-04-05 IL IL251600A patent/IL251600A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2013000333A (es) | 2013-02-26 |
US9102620B2 (en) | 2015-08-11 |
AR082150A1 (es) | 2012-11-14 |
PE20130396A1 (es) | 2013-04-19 |
CL2013000063A1 (es) | 2013-05-03 |
EA201390081A1 (ru) | 2013-07-30 |
EP3213636A1 (en) | 2017-09-06 |
AU2011274496B2 (en) | 2016-03-10 |
CN104610144A (zh) | 2015-05-13 |
JP2013535437A (ja) | 2013-09-12 |
EA025377B1 (ru) | 2016-12-30 |
NZ606587A (en) | 2015-03-27 |
US20140051723A1 (en) | 2014-02-20 |
SG10201505236YA (en) | 2015-08-28 |
US20140343096A1 (en) | 2014-11-20 |
KR20130092558A (ko) | 2013-08-20 |
CA2804986A1 (en) | 2012-01-12 |
IL251600A0 (en) | 2017-06-29 |
US8580819B2 (en) | 2013-11-12 |
CN102984939A (zh) | 2013-03-20 |
WO2012006538A1 (en) | 2012-01-12 |
US20120010238A1 (en) | 2012-01-12 |
EP2597954A1 (en) | 2013-06-05 |
ZA201300956B (en) | 2014-04-30 |
WO2012006538A8 (en) | 2013-05-23 |
UY33504A (es) | 2012-02-29 |
SG186948A1 (en) | 2013-02-28 |
AU2011274496A1 (en) | 2013-02-28 |
JP2017014238A (ja) | 2017-01-19 |
EP2597954A4 (en) | 2014-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013000599A2 (pt) | deuterado n-etil-n-fenil-1,2-di-hidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolino-3-carboxamida, os seus sais e suas utilizações | |
BR112013000607A2 (pt) | 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações | |
BR112015010436A2 (pt) | Anticorpos anti-notch3 e conjugados anticorpo-fármaco | |
JP2014501485A5 (pt) | ||
UY34456A (es) | Anticuerpos anti-il-36r | |
UY4211Q (es) | Pizarra para marcadores | |
EA201390613A1 (ru) | Обогащенный дейтерием расагилин | |
UY34582A (es) | Anticuerpos anti-cxcr3 | |
BR112016009488A8 (pt) | piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica. | |
UY4210Q (es) | Silla | |
BR112013005855A2 (pt) | heteroarilas fundidas e seus usos | |
UY4281Q (es) | Juguera | |
UY4223Q (es) | Banco | |
BR112013030540A2 (pt) | tecido elástico. | |
UY34416A (es) | ?sales de herbicidas de ácido carboxílico? | |
CL2009001973S1 (es) | Mostrador. | |
UY4248Q (es) | Silla | |
BR112015002986A2 (pt) | adjuvante de adesividade, adjuvante de espalhamento-adesividade, e, composição agroquímica | |
CL2011002741S1 (es) | Reposera. | |
UY33207A (es) | Métodos de preparación de tiazolidinas | |
TR201111860U (tr) | Rozetli bariyer. | |
CL2012002141S1 (es) | Silla | |
CL2012002142S1 (es) | Silla | |
CL2012002143S1 (es) | Silla | |
CL2012002144S1 (es) | Silla |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |